RxDoctor Payments Data

Cassandra Gonzalez-Hernandez, PA

Physician Assistant · Springville, UTNPI 1720734106

Payments from drug & device makers

$2,001in general payments, 2019–2025

Across 131 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$607
  • AbbVie$269
  • Abbott$240
  • Dexcom, Inc.$172
  • Sanofi-aventis U.S. LLC$93
  • Lilly USA, LLC$80
  • plus $539 from 16 others

What the payments were for

  • Food & beverage$2,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,001 in reported general payments places this provider in the 80th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$108,026
Medicare patients
195
Services billed
4,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide195$245,202
MounjaroTirzepatide178$225,220
JardianceEmpagliflozin103$86,931
ProliaDenosumab49$85,299
TrulicityDulaglutide45$76,570
RybelsusSemaglutide57$56,894
FarxigaDapagliflozin Propanediol63$45,226
Tresiba Flextouch U-200Insulin Degludec22$35,966
Tresiba Flextouch U-100Insulin Degludec38$28,474
Humulin R U-500 KwikpenInsulin Regular, Human12$23,277
Lantus SolostarInsulin Glargine,hum.Rec.Anlog146$21,207
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$19,372
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$18,827
Novolog FlexpenInsulin Aspart67$17,747
Humalog Kwikpen U-100Insulin Lispro51$13,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$607$302,096252 claims
Lilly USA, LLCMounjaro, Trulicity$80$301,790223 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$32$100,839134 claims
AbbVieSynthroid$269$2,42431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Springville

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →